Cargando…
Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)
BACKGROUND: There is no generally accepted methodology for in vivo assessment of antiviral activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment of COVID-19, but whether it has clinically significant antiviral activity in vivo is uncertain. METHODS: In a multicentr...
Ejemplares similares
-
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)
por: Jittamala, Podjanee, et al.
Publicado: (2023) -
Rickettsiosis in Southeast Asia: Summary for International Travellers during the COVID-19 Pandemic
por: Ngamprasertchai, Thundon, et al.
Publicado: (2022) -
Efficacy and Safety of Immunomodulators in Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Ngamprasertchai, Thundon, et al.
Publicado: (2021) -
Temperature Dependence of Plasmodium falciparum Erythrocytic Stage Development
por: Singhaboot, Yutatirat, et al.
Publicado: (2019) -
Artemisinin resistance and malaria elimination: Where are we now?
por: Hanboonkunupakarn, Borimas, et al.
Publicado: (2022)